U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07695701) titled 'Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis' on July 06.
Brief Summary: The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Amyloidosis
Amyloid Cardiomyopathy
Transthyretin Amyloidosis
Intervention:
DRUG: Acoramidis (AG10) oral tablet
Study drug is defined as acoramidis 712 mg (equivalent to 800 mg acoramidis HCl) taken orally twice daily for 36 months of open label treatment.
Recruitment Status: NOT_YET_R...